A Breakthrough Treatment for Cancer and Autoimmune Disorders – Mozocare Insights

Through Mozocare’s integrated medical access platform,
patients can explore approved and advanced CAR-T therapy options in China, particularly for blood cancers and multiple myeloma.

CAR-T for Lymphoma

China offers cutting-edge CAR-T products and protocols for aggressive and treatment-resistant lymphomas, including:

These therapies have shown strong efficacy in patients with relapsed or refractory lymphoma who have exhausted standard treatment options.

CAR-T for Leukemia

For patients with B-cell acute lymphoblastic leukemia (B-ALL), CAR-T therapy has demonstrated remarkable remission rates.
Available options in China include:

CAR-T for Multiple Myeloma

Multiple myeloma, a complex and often relapsing blood cancer, is another area where CAR-T therapy is redefining outcomes.
China-based options include:

These therapies target BCMA (B-cell maturation antigen) and have delivered significant responses in patients with advanced or relapsed
disease.